Abstract PET has become an important clinical modality but is limited to imaging positron emitters. Recently, with 89 Zr, which a half-life of 3 days, attracted much attention in immuno-PET visualize immune cells and cancer by targeting specific antibodies on the cell surface. However, Zr emits single gamma ray at 909 keV four times more frequently than positrons, causing image quality degradation conventional PET. To overcome this drawback, use such rays for was previously proposed as whole...

Radiometal-labeled peptide-based radiopharmaceuticals (RLPB-radiopharmaceuticals) are promising for cancer imaging and targeted radiotherapy; however, their effectiveness is often compromised by the high retention of nonspecific radioactivity in kidneys due to renal excretion pathways. Current strategies address this issue have limitations, highlighting need innovative approaches improve targeting specificity therapeutic efficacy. We aimed evaluate applicability Gly-Phe-Lys (GFK) tripeptide,...

The worldwide incidence of the highly aggressive tumor mesothelioma is expected to increase. Mesothelioma classified into three main histological subtypes: epithelioid, sarcomatoid and biphasic. Although pathological diagnostic markers for epithelioid are established, date no adequate marker has been found. Thus, a reliable necessary. In this study, identify an unknown protein with 120 kDa expressed only in cell line 211H, we conducted proteomic analysis found five candidate proteins. One...

The transmembrane cell adhesion receptor αVβ3 integrin (αVβ3) has been identified as an important molecular target for cancer imaging and therapy. We have developed a tetrameric cyclic RGD (Arg-Gly-Asp) peptide-based radiotracer (64)Cu-cyclam-RAFT-c(-RGDfK-)4, which successfully captured αVβ3-positive tumors angiogenesis by PET. Here, we subsequently evaluated its therapeutic potential side effects using established tumor mouse model. Mice with subcutaneous U87MG glioblastoma xenografts...

Synovial sarcoma ( SS ) is a rare yet refractory soft‐tissue that predominantly affects young adults. We show in mouse model radioimmunotherapy RIT with an α‐particle emitting anti‐Frizzled homolog 10 FZD 10) antibody, synthesized using the α‐emitter radionuclide astatine‐211 211 At‐ OTSA 101), suppresses growth of xenografts more efficiently than corresponding β‐particle anti‐ antibody conjugated β‐emitter yettrium‐90 90 Y‐ 101). In biodistribution analysis, At was increased but decreased...

Pancreatic cancer (PC) has a very poor prognosis. Surgery is the primary treatment for patients with resectable PC; however, local recurrence, hepatic metastasis, and peritoneal dissemination often occur even after extensive surgery. Adjuvant chemotherapy, typically gemcitabine, been used clinically but only modest survival benefit. To achieve better outcome, we investigated efficacy of ⁶⁴Cu-intraperitoneal radioimmunotherapy (ipRIT) ⁶⁴Cu-labeled antiepidermal growth...

Introduction Pancreatic cancer is an aggressive and its prognosis remains poor. Therefore, additional effective therapy required to augment and/or complement current therapy. CD147, high expression in pancreatic cancer, involved the metastatic process considered a good candidate for targeted CD147-specfic imaging could be useful selection of appropriate patients. we evaluated potential fully human anti-CD147 monoclonal antibody 059-053 as new positron emission tomography (PET) probe cancer....

Objective Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of more effective therapy needed. We previously reported that 89Zr-labeled TSP-A01, antibody against transferrin receptor (TfR), highly accumulated in a pancreatic xenograft, but not major normal organs. In present study, we evaluated efficacy radioimmunotherapy (RIT) with 90Y-TSP-A01 mouse models. Methods TfR expression cell lines (AsPC-1, BxPC-3, MIAPaCa-2) was by immunofluorescence...

To investigate near-infrared photoimmunotherapeutic effect mediated by an anti-tissue factor (TF) antibody conjugated to indocyanine green (ICG) in a pancreatic cancer model.Near-infrared photoimmunotherapy (NIR-PIT) is highly selective tumor treatment that utilizes antibody-photosensitizer conjugate administration, followed NIR light exposure. Anti-TF 1849-ICG was synthesized labeling of rat IgG2b anti-TF monoclonal 1849 (anti-TF 1849) photosensitizer, ICG. The expression levels TF two...

The α-emitter 211At-labeled meta-astatobenzylguanidine (211At-MABG) has a strong antitumor effect on pheochromocytoma xenograft tumors and holds great promise as new therapeutic option for malignant pheochromocytoma. To evaluate the acute radiation-related toxicity of 211At-MABG, we conducted biodistribution dosimetry studies 211At-MABG in ICR mice to estimate doses absorbed by organs. We determined maximum tolerated (MTD) basis body weight loss assessed induced MTD administration organ...

Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) overexpressed most synovial sarcomas, making it a promising therapeutic target. results phase 1 trial β-radioimmunotherapy (RIT) the 90 Y-labeled anti-FZD10 antibody OTSA101 revealed need improved efficacy. present study evaluated potential α-RIT labeled α-emitter 225 Ac. Competitive inhibition cell...

Mesothelioma is an aggressive tumor caused by asbestos exposure, the incidence of which predicted to increase globally. The prognosis patients with mesothelioma undergoing conventional therapy poor. Radiation for limited use because intrinsic radioresistance cells compared surrounding normal tissue. Thus, a novel molecular-targeted radiosensitizing agent that enhances radiosensitivity required improve therapeutic efficacy radiation therapy. ZDHHC8 knockdown reduces cell survival and induces...

Small cell lung cancer (SCLC) is an aggressive tumor and prognosis remains poor. Therefore, the development of more effective therapy needed. We previously reported that high levels anti-c-kit antibody (12A8) accumulated in SCLC xenografts. In present study, we evaluated efficacy two antibodies (12A8 67A2) for radioimmunotherapy (RIT) mouse model by labeling with 90Y isotope. Methods 111In- or 125I-labeled were vitro binding, competitive inhibition cellular internalization assays...

Copper-67 (Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated developing innovative approaches large-scale production Cu. Encouraged by these, we performed Cu-radiolabeling a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis. We also evaluated...

Pancreatic cancer is aggressive and its prognosis remains poor; thus, effective therapy urgently needed. Transferrin receptor (TfR) highly expressed in pancreatic considered to be a good candidate for molecular-targeted therapy. We radiolabeled evaluated fully human anti-TfR monoclonal antibodies as new PET probe evaluating the biodistribution of antibody cancer.TfR expression was four (MIAPaCa-2, PANC-1, BxPC-3, AsPC-1) murine A4 cell lines. The binding 125I-labeled (TSP-A01, TSP-A02,...

// Yukie Yoshii 1 , Mitsuyoshi Yoshimoto 2 Hiroki Matsumoto 3 Hideaki Tashima Yuma Iwao Hiroyuki Takuwa Eiji Yoshida Hidekatsu Wakizaka Taiga Yamaya Ming-Rong Zhang Aya Sugyo Sayaka Hanadate Atsushi B. Tsuji and Tatsuya Higashi National Institute of Radiological Sciences, Institutes for Quantum Science Technology, Chiba, Japan Division Functional Imaging, Cancer Center Hospital East, Research Center, Nihon Medi-Physics Co., Ltd., Correspondence to: Yoshii, email: yoshii.yukie@qst.go.jp...

HER3 is overexpressed in various carcinomas including colorectal cancer (CRC), which associated with poor prognosis, and involved the development of therapy resistance. Thus, an vivo imaging technique needed to evaluate expression HER3, important therapeutic diagnostic target. Here, we report successful PET using a newly generated anti-human monoclonal antibody, Mab#58, mouse model HER3-overexpressing xenograft tumor. Furthermore, assessed role signaling CRC tissue-originated spheroid (CTOS)...

Scirrhous gastric cancer (SGC) is a recalcitrant tumor, which among the most lethal cancers. A critical issue for improvement of SGC prognosis lack an effective imaging method accurate detection and diagnosis. Because combined nuclear medicine with magnetic resonance (MRI) has ability to detect high sensitivity, quantitation spatial resolution, it potential overcome issues detection. Herein, we designed synthesized new block copolymer poly(ethylene glycol)-b-poly(γ-benzyl l-glutamate) linked...

Abstract Pancreatic cancer (PC) has a poor prognosis owing to difficulties in the diagnosis of resectable PC at early stages. Several clinical studies have indicated that detection and surgery small (<1 cm) can significantly improve survival; however, imaging accurate resection remain challenging. Here, we report feasibility “immuno-OpenPET” as novel approach enabling not only but also image-guided surgery, using orthotopic xenograft mouse model. For immuno-OpenPET, utilized our original...

The prognosis of advanced mesothelioma is poor. Podoplanin (PDPN) highly expressed in most malignant mesothelioma. This study aimed to evaluate the potential alpha-radioimmunotherapy (RIT) with a newly developed anti-PDPN antibody, NZ-16, compared previous NZ-12. Methods: vitro properties radiolabeled antibodies were evaluated by cell binding and competitive inhibition assays using PDPN-expressing H226 cells. biodistribution 111In-labeled was studied tumor-bearing mice. absorbed doses...

The poor prognosis of pancreatic cancer requires the development more effective therapy. CD147 expresses in with high incidence and has a crucial role invasion metastasis. We developed fully human monoclonal antibody (059-053) affinity for CD147. Here we evaluated efficacy combined treatment using radioimmunotherapy (RIT) 90Y-labeled 059-053 gemcitabine BxPC-3 xenograft mouse model. Expression matrix metalloproteinase-2 (MMP2) tumors was evaluated. In vitro vivo properties were 111In-labeled...